Well-funded biotech RHY kicks off CSIRO contract
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
The ASX-listed biotech Rhythm Biosciences (ASX:RHY) — a developer of the ColoSTATTM antibody based blood test targeting the accurate and early detection of colorectal cancer — this week released its first quarterly report.
RHY listed on the ASX on 7 December 2017.
Since then it has signed a key research contract with CSIRO to complete development of the key reagents needed for ColoSTATTM.
The company’s lead product is intended to provide the accurate and early detection of colorectal cancer, acting as either a ‘first-step’ screening test or as a step following a positive faecal immunochemical test (FIT) or colonoscopy.
Importantly, ColoSTATTM is also of particular value to those with risk factors associated with colorectal cancer. The technology also has the potential to become the new first step screening test for people, who for personal, cultural or clinical reasons, elect to not participate in the existing screening programs for colorectal cancer.
It is designed to be a simple blood test that is cost effective, minimally invasive and easily run by laboratories with minimal training or need for new infrastructure — which can simultaneously achieve greater patient participation and compliance than faecal tests.
It should be noted here that RHY is in its early stages and investors should seek professional financial advice if considering this stock for their portfolio.
Key contract with CSIRO has commenced
Within days of listing on the ASX in December, RHY informed the market it had kicked off work under its research contract with the Commonwealth Scientific and Industrial Research Organisation (CSIRO) to develop the last key reagents required for ColoSTATTM.
This coincides with the company’s explicit objective to develop its own antibodies and target proteins which would allow RHY to control the supply, quality and cost of the key reagents required to manufacture the ColoSTATTM test kits. The reagents are a crucial factor in terms of producing test kits that are consistent and reliable.
While the company already has its own reagents for most of the ColoSTATTM targets, as specified in the CSIRO contract, researchers will develop these target reagents and assess their advantages over reagents that are already commercially available.
Delivery of the key reagents and ‘cell lines’ required for truly scalable and ongoing production is expected by RHY to come through in late November this year. Once it has those in place. The company can progress ColoSTATTM to a new production and validation phase.
$8.79M cash on hand as at 31 December
As mentioned, RHY commenced trading on the ASX on 7 December 2017.
RHY’s directors are pleased with the company’s progress since listing, with Chairman Shane Tanner stating: “We remain driven at achieving key deliverables under the company’s business plan to expedite the development and commercialisation of ColoSTAT.
“We are fully funded and remain on track to achieve such strategic objectives under the business plan.”
General Information Only
This material has been prepared by Jason Price. Jason Price is an authorised representative (AR 000296877) of 62 Consulting Pty Limited (ABN 88 664 809 303) (AFSL 548573) (62C), and a Director of S3 Consortium Pty Ltd (trading as StocksDigital).
This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by 62C, Jason Price, StocksDigital, any of their related body corporates or any other person. To the maximum extent possible, 62C, Jason Price, StocksDigital, their related body corporates or any other person do not accept any liability for any statement in this material.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
